Given orphan drugs are intended to treat diseases that are very complex and diverse, development is often seen as a risk for the industry – requiring several years of research efforts in drug discovery with uncertainty for therapeutic outcomes.
By starting out with a complete clinical picture via multi-omic data, consisting of genomics, transcriptomics, proteomics, metabolomics, and phenomics data, we can now gain multilayer insights that help us develop better disease models and thus more precise medicine.
This session will focus on examples and emerging applications that demonstrate how multi-omic data can be leveraged to accelerate and de-risk rare disease drug discovery and development.
Justin Bingham joined CENTOGENE in 2017 and leads the Company’s business development and commercialization activities across pharma and biotech. Justin is a seasoned business executive with a track record of executing high value and successful partnerships within the healthcare sector. He brings vast experience in the commercialization of cutting-edge technologies that utilize high powered genomic sequencing. Prior to his role at CENTOGENE, Justin led business development activities for Synthetic Genomics, Inc. (SGI) across several industries, including vaccines, pharma, and life sciences. Additionally, Justin has held research positions at the Genomics Institute of the Novartis Research Foundation (GNF) and the exploratory biology research group at Pfizer, Inc. Justin completed his undergraduate work in Molecular Biology at the University of California, Santa Cruz, and holds an MBA from the Rady School of Business at the University of California, San Diego.
Michael is the CEO of EB Research Partnership, an innovative medical research organization dedicated to curing the life-threatening genetic skin disease Epidermolysis Bullosa (EB) and leading the way for rare diseases with a pioneering venture investing and technology business model. Michael previously served as the Director of Development for the Multiple Myeloma Research Foundation leading their successful $100 million Curing Cancer Now campaign. Previously, Michael spent over a decade in leadership at the actor and philanthropist Paul Newman’s Hole in the Wall Gang Fund, working on behalf of children and their families battling cancer and other life-threatening illness. Michael received his MBA from Yale University, CORe credential from Harvard Business School, and an undergraduate degree in Philosophy from the University of Kansas.
Research focuses on developing novel methods for leveraging heterogeneity present across independent cohorts to better understand human immune system for developing novel diagnostics and therapies for inflammatory diseases